Phase 3 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have experienced a first episode of psychosis that began within the last 2 years, or who have an attenuated (mild/early) psychosis syndrome, and whose condition has been stabilised with treatment for at least 8 weeks
- People who have been clinically stable and not in an acute (crisis) phase of their illness for at least 2 months
- People with a first episode of psychosis who have been on their current antipsychotic medication for at least 6 weeks, with no change in dose for the past 4 weeks
- People with attenuated psychosis syndrome who have been on the same treatment plan (whether therapy-based or medication-based) for at least 4 weeks
- People whose positive symptoms (such as delusions, hallucinations, or disorganised thinking) are no more than moderate in severity, based on a standard rating scale score
- People who have no more than minimal levels of depression, as measured by a standard depression rating scale for schizophrenia
- People whose diagnosis falls into one of these categories (as confirmed by a structured clinical interview): attenuated psychosis syndrome, psychosis not otherwise specified, schizophreniform disorder, schizophrenia, or schizoaffective disorder
Who may not be able to join:
- People who have a significant medical or neurological condition alongside their psychiatric diagnosis
- People who have had a significant head injury
- People whose intellectual functioning (IQ) is below 80 (though people with an IQ between 75 and 79 may still be considered if reading ability testing suggests their prior functioning was higher — confirm with trial site)
- People assessed as being at high risk of suicide, based on a standard suicide risk rating scale
- People who are pregnant, or who are not willing to avoid becoming pregnant during the trial
- People who require treatment with any of the following medications: Azelastine, Azelastine with Fluticasone, Dronabinol, Valproic Acid, or Divalproex Sodium
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kristin Cadenhead, MD, University of California, San Diego
Phone: 619-543-6445
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Positive and Negative Symptoms of Psychosis; Neurocognition; Prodromal Symptoms; General Symptoms; Clinical Global Impression Scale (CGI-S)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.